{"filing":{"accession_number":"0001472375-26-000214","cik":"0001357878","ticker":"RGPX","company_name":"REGENEREX PHARMA, INC.","form":"8-K","filing_date":"2026-09-01","report_date":"2026-09-01","primary_document":"ixform8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1357878/000147237526000214/ixform8k.htm"},"events":[{"id":30908,"run_id":28343,"accession_number":"0001472375-26-000214","anchor_item_number":"8.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.85,"summary":"The Company discloses delinquent quarterly filings (10-Qs for Q1 and Q2 2026) and a late annual filing (2025 10-K filed after deadline), with failure to file timely Form 12b-25 notifications. These reporting delinquencies create material delisting risk under exchange continued listing standards, which typically require timely periodic report filings. While the disclosure does not explicitly mention delisting notice, the pattern of missed deadlines and acknowledged non-compliance with SEC filing obligations directly threatens the Company's exchange listing status.","company_name":"REGENEREX PHARMA, INC.","ticker":"RGPX","filing_date":"2026-09-01","form":"8-K","submitted_at":null,"items":[{"id":33646,"accession_number":"0001472375-26-000214","item_number":"8.01","item_title":"Other Events","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.85,"reasoning":"The Company discloses delinquent quarterly filings (10-Qs for Q1 and Q2 2026) and a late annual filing (2025 10-K filed after deadline), with failure to file timely Form 12b-25 notifications. These reporting delinquencies create material delisting risk under exchange continued listing standards, which typically require timely periodic report filings. While the disclosure does not explicitly mention delisting notice, the pattern of missed deadlines and acknowledged non-compliance with SEC filing obligations directly threatens the Company's exchange listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T18:13:39.129610+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33646,"accession_number":"0001472375-26-000214","item_number":"8.01","item_title":"Other Events","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.85,"reasoning":"The Company discloses delinquent quarterly filings (10-Qs for Q1 and Q2 2026) and a late annual filing (2025 10-K filed after deadline), with failure to file timely Form 12b-25 notifications. These reporting delinquencies create material delisting risk under exchange continued listing standards, which typically require timely periodic report filings. While the disclosure does not explicitly mention delisting notice, the pattern of missed deadlines and acknowledged non-compliance with SEC filing obligations directly threatens the Company's exchange listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T18:13:39.129610+00:00","company_name":"REGENEREX PHARMA, INC.","ticker":"RGPX","filing_date":"2026-09-01"}]}